Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co Total Assets

The Total Assets of Harbin Pharmaceutical Group Co (600664.SS) as of Nov 14, 2026 is 14.29 B CNY. In the previous year, Total Assets was 14.62 B CNY — a change of -2.24% (lower).

Total Assets

14.29 BCNY

YoY

-2.24%

Last updated:

Total Assets of Harbin Pharmaceutical Group Co is 2025 14.29 B CNY. Total Assets of Harbin Pharmaceutical Group Co was 2024 14.62 B CNY. It decreases by -2.24% lower compared to the previous year.

The Harbin Pharmaceutical Group Co Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
11.90 B CNY
Jan 1, 2019
12.50 B CNY
Jan 1, 2020
11.85 B CNY
Jan 1, 2021
12.84 B CNY
Jan 1, 2022
13.44 B CNY
Jan 1, 2023
14.11 B CNY
Jan 1, 2024
14.62 B CNY
Jan 1, 2025
14.29 B CNY
The Harbin Pharmaceutical Group Co Total Assets history
YEARTotal AssetsYoY
14.29 BCNY-2.24%
14.62 BCNY+3.57%
14.11 BCNY+5.03%
13.44 BCNY+4.62%
12.84 BCNY+8.40%
11.85 BCNY-5.24%
12.50 BCNY+5.06%
11.90 BCNY-13.13%
13.70 BCNY-8.99%
15.05 BCNY+9.35%
13.77 BCNY-15.25%
16.24 BCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

Total Assets of Harbin Pharmaceutical Group Co is 14.29 B CNY in 2025.

Total Assets of Harbin Pharmaceutical Group Co changed from 14.62 B CNY to 14.29 B CNY, representing a -2.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Harbin Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Harbin Pharmaceutical Group Co

All Key Metrics — Harbin Pharmaceutical Group Co